139 related articles for article (PubMed ID: 25675650)
21. Drug resistance patterns in Mycobacterium leprae isolates from relapsed leprosy patients attending The Leprosy Mission (TLM) Hospitals in India.
Lavania M; Jadhav RS; Chaitanya VS; Turankar R; Selvasekhar A; Das L; Darlong F; Hambroom UK; Kumar S; Sengupta U
Lepr Rev; 2014 Sep; 85(3):177-85. PubMed ID: 25509718
[TBL] [Abstract][Full Text] [Related]
22. Six years' follow-up of multibacillary leprosy patients treated with uniform multi-drug therapy in China.
Shen J; Yan L; Yu M; Li J; Yu X; Zhang G
Int J Dermatol; 2015 Mar; 54(3):315-8. PubMed ID: 25265933
[TBL] [Abstract][Full Text] [Related]
23. Disabilities in multibacillary leprosy following multidrug therapy with and without immunotherapy with Mycobacterium w antileprosy vaccine.
Sharma P; Kar HK; Misra RS; Mukherjee A; Kaur H; Mukherjee R; Rani R
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):250-8. PubMed ID: 10575404
[TBL] [Abstract][Full Text] [Related]
24. OFLOXACIN multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil.
Cunha Mda G; Virmond M; Schettini AP; Cruz RC; Ura S; Ghuidella C; Viana Fdos R; Avelleira JC; Campos AA; Filho B
Lepr Rev; 2012 Sep; 83(3):261-8. PubMed ID: 23356027
[TBL] [Abstract][Full Text] [Related]
25. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.
Cellona RV; Balagon MF; dela Cruz EC; Burgos JA; Abalos RM; Walsh GP; Topolski R; Gelber RH; Walsh DS
Int J Lepr Other Mycobact Dis; 2003 Dec; 71(4):308-19. PubMed ID: 14763888
[TBL] [Abstract][Full Text] [Related]
26. Comparison of PCR mediated amplification of DNA and the classical methods for detection of Mycobacterium leprae in different types of clinical samples in leprosy patients and contacts.
Torres P; Camarena JJ; Gomez JR; Nogueira JM; Gimeno V; Navarro JC; Olmos A
Lepr Rev; 2003 Mar; 74(1):18-30. PubMed ID: 12669929
[TBL] [Abstract][Full Text] [Related]
27. Comparative study of uniform-MDT and WHO MDT in Pauci and Multi bacillary leprosy patients over 24 months of observation.
Rao PN; Suneetha S; Pratap DV
Lepr Rev; 2009 Jun; 80(2):143-55. PubMed ID: 19743618
[TBL] [Abstract][Full Text] [Related]
28. Are viable Mycobacterium leprae present in lepromatous patients after completion of 12 months' and 24 months' multi-drug therapy?
Ebenezer GJ; Daniel S; Norman G; Daniel E; Job CK
Indian J Lepr; 2004; 76(3):199-206. PubMed ID: 15835604
[TBL] [Abstract][Full Text] [Related]
29. Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years.
Shaw IN; Natrajan MM; Rao GS; Jesudasan K; Christian M; Kavitha M
Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):405-9. PubMed ID: 11332283
[TBL] [Abstract][Full Text] [Related]
30. Clinical, histopathological and bacteriological study of 52 referral MB cases relapsing after MDT.
Shetty VP; Wakade AV; Ghate SD; Pai VV; Ganapati RR; Antia NH
Lepr Rev; 2005 Sep; 76(3):241-52. PubMed ID: 16248211
[TBL] [Abstract][Full Text] [Related]
31. Three years assessment of multidrug therapy in multibacillary leprosy cases.
Ganapati R; Revankar CR; Pai RR
Indian J Lepr; 1987; 59(1):44-9. PubMed ID: 3611860
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of MDT in multibacillary leprosy.
Jesudasan K; Vijayakumaran P; Manimozhi N; Rao PS; Samuel P
Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):128-32. PubMed ID: 8690970
[TBL] [Abstract][Full Text] [Related]
33. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy.
Chen XS; Li WZ; Jiang C; Ye GY
Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):379-87. PubMed ID: 10700911
[TBL] [Abstract][Full Text] [Related]
34. Nasal mucosa and skin of smear-positive leprosy patients after 24 months of fixed duration MDT: histopathological and microbiological study.
Ebenezer GJ; Job A; Abraham S; Arunthathi S; Rao PS; Job CK
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):292-7. PubMed ID: 10575409
[TBL] [Abstract][Full Text] [Related]
35. Long-term relapse risk of multibacillary leprosy after completion of 2 years of multiple drug therapy (WHO-MDT) in Cebu, Philippines.
Balagon MF; Cellona RV; Cruz Ed; Burgos JA; Abalos RM; Walsh GP; Saunderson PR; Walsh DS
Am J Trop Med Hyg; 2009 Nov; 81(5):895-9. PubMed ID: 19861628
[TBL] [Abstract][Full Text] [Related]
36. Does clofazimine prevent erythema nodosum leprosum (ENL) in leprosy? A retrospective study, comparing the experience of multibacillary patients receiving either 12 or 24 months WHO-MDT.
Balagon M; Saunderson PR; Gelber RH
Lepr Rev; 2011 Sep; 82(3):213-21. PubMed ID: 22125929
[TBL] [Abstract][Full Text] [Related]
37. Fixed-duration multidrug therapy in multibacillary leprosy.
Li HY; Hu LF; Wu PW; Luo JS; Liu XM
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):230-7. PubMed ID: 9251596
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of lepromin-negative borderline leprosy patients with low-dose Convit vaccine as an adjunct to multidrug therapy; a six-year follow-up study in Calcutta.
Chaudhury S; Hajra SK; Mukerjee A; Saha B; Majumdar V; Chattapadhya D; Saha K
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):56-62. PubMed ID: 9207754
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics and outcome in multibacillary (MB) leprosy patients treated with 12 months WHO MDT-MBR: a retrospective analysis of 730 patients from a leprosy clinic at a tertiary care hospital of Northern India.
Dogra S; Kumaran MS; Narang T; Radotra BD; Kumar B
Lepr Rev; 2013 Mar; 84(1):65-75. PubMed ID: 23741883
[TBL] [Abstract][Full Text] [Related]
40. [Chemotherapy of leprosy: theoretical basis of new guideline in Japan].
Goto M
Nihon Hansenbyo Gakkai Zasshi; 2001 Aug; 70(3):151-5. PubMed ID: 11579514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
